Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| License and milestone revenues | — | 64,353 | 11,929 | 64,353 |
| Total revenues | 28,624 | 66,769 | 47,979 | 68,348 |
| Operating expenses: | ||||
| Research and development | 97,807 | 110,138 | 193,332 | 208,400 |
| Selling, general and administrative | 104,397 | 65,721 | 209,293 | 123,090 |
| Cost of goods sold | 2,731 | — | 2,891 | — |
| Collaboration cost of revenues | 2,861 | 2,416 | 5,253 | 3,995 |
| Total operating expenses | 207,796 | 178,275 | 410,769 | 335,485 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's R&D?
- Cytokinetics (CYTK) reported R&D of $97.81M in Q2 2026.
- How has Cytokinetics's R&D changed year-over-year?
- Cytokinetics's R&D decreased by 11.2% year-over-year, from $110.14M to $97.81M.
- What is the long-term trend for Cytokinetics's R&D?
- Over 4 years (2021 to 2025), Cytokinetics's R&D has grown at a 26.7% compound annual growth rate (CAGR), from $159.94M to $412.03M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Cytokinetics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude